Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology Pharmaceuticals STAT+jobs biotechnology | Pharmaceuticals | STAT+

	Profile	Recent Articles on Subject
1	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 3 days ago STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending - 3 days ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study - 4 days ago STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 5 days ago STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 6 days ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - about 1 month ago STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried - 3 months ago STAT+: A scientific mystery highlights the blind spots in genomics databases - 6 months ago STAT+: Results on Novartis prostate cancer therapy could expand its use - 11 months ago STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit - 12 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago
4	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 7 days ago STAT+: Tome Biosciences files notice to lay off virtually entire staff - 27 days ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 28 days ago STAT+: Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy - 3 months ago STAT+: Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff - 7 months ago
5	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 7 days ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 14 days ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 14 days ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - about 1 month ago STAT+: On Andrew Left and the government’s fraud case - about 2 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 5 months ago STAT+: Weed for weight loss, and more from Biotech Land - 6 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 6 months ago STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch - 9 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - 9 months ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - 11 months ago
7	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: Humana cutting Medicare Advantage plans that cover 10% of members - 15 days ago STAT+: UnitedHealthcare’s latest contract dispute, this time with Trinity Health, leaves thousands out-of-network - about 1 month ago STAT+: Elevance tumbles as health insurer warns Medicaid members are using more care - 2 months ago
8	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 15 days ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 28 days ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 4 months ago STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials - 6 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 6 months ago STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO - 6 months ago STAT Virtual Event \| 2024 JPM Recap, Live! - 8 months ago
9	Casey Ross STAT News National health tech writer @statnews. Covers #AI, #digitalhealth. Cleveland, OH health technologyjournalismartificial intelligencedigital health	STAT+: AI in medicine: A national registry could help increase transparency, experts say - 27 days ago STAT Virtual Event: Putting AI to the Test - 12 months ago
10	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: What to know about Alnylam’s upcoming readout on its heart drug - about 1 month ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 6 months ago

Journalists covering STAT+